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TreatmentAbstract Objective: To investigate current status of diagnosis and treatment of bladder can-
cer in China.
Methods: A database was generated by Chinese Bladder Cancer Consortium (CBCC). From
January 2007 to December 2012, 14,260 cases from 44 CBCC centers were included. Data of
diagnosis, treatment and pathology were collected.
Results: The average age was 63.5 year-old and most patients were male (84.3%). The most
common histologic types were urothelial carcinoma (91.4%), adenocarcinoma (1.8%), and
Bladder cancer in China: A report of CBCC 65squamous carcinoma (1.9%). According to 1973 and 2004 WHO grading system, 42.0%, 41.0%,
and 17.0% of patients were grade 1, 2, and 3, and 16.0%, 48.7%, and 35.3% of patients were
papillary urothelial neoplasms of low malignant potential, low, and high grade, respectively.
Non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) were
25.2% and 74.1%, respectively (0.8% not clear). Carcinoma in situ was only 2.4%. Most patients
were diagnosed by white-light cystoscopy with biopsy (74.3%). Fluorescence and narrow band
imaging cystoscopy had additional detection rate of 1.0% and 4.0%, respectively. Diagnostic
transurethral resection (TUR) provided detection rate of 16.9%. Most NMIBCs were treated with
TUR (89.2%). After initial TUR, 2.6% accepted second TUR, and 45.7%, 69.9%, and 58.7%
accepted immediate, induced, and maintenance chemotherapy instillation, respectively. Most
MIBCs were treated with radical cystectomy (RC, 59.7%). Laparoscopic RCs were 35.1%, while
open RC 63.4%. Extended and standard pelvic lymph node dissection were 7% and 66%, respec-
tively. Three most common urinary diversions were orthotopic neobladder (44%), ileal conduit
(31%), and ureterocutaneostomy (23%). Only 2.3% of patients accepted neo-adjuvant chemo-
therapy and only 18% of T3 and T4 patients accepted adjuvant chemotherapy.
Conclusion: Disease characteristics are similar to international reports, while differences of
diagnosis and treatment exist. This study can provide evidences for revisions of the guideline
on bladder cancer in China.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bladder cancer (BCa) is the most common urologic malig-
nancy in China. During the past few years, the incidence
and mortality rates have increased gradually [1,2]. How-
ever, most data referred for guideline of Chinese BCa are
not originally from China [3]. In fact, discriminations of
diagnosis and treatment in practice for BCa may exist be-
tween China and Western countries. To gain unique data of
BCa in China, Chinese Bladder Cancer Consortium (CBCC)
conducted a cross-sectional investigation in 44 membership
centers and generated a database of BCa. From January
2007 to December 2012, clinical data of 14,260 BCa cases
were retrospectively collected. The present study was to
investigate the current status of diagnosis and treatment
for Chinese BCa by analyzing the database and to give ev-
idences for Chinese guideline.
2. Patients and methods
2.1. Patients
The CBCC includes 44 academic centers from China. This
study was approved by Institutional Review Boards in all
CBCC centers. An electronic CBCC database was generated
for data transfer and collection. Before data analysis,
initial verifications were performed for identifying data
consistencies and integrity. Communication with CBCC
centers permitted resolution of identified anomalies. In all,
14,260 in-patient cases diagnosed as BCa from January 1,
2007 to December 31, 2012 were included.
2.2. Clinical features
The clinical features evaluated included age, gender, body
mass index (BMI), prior history of bladder cancer, ways ofdiagnosis and treatment (transurethral resection [TUR],
radical cystectomy [RC], partial cystectomy [PC] and
others), perioperative information, histology, pathological
T stage and grade, instillation therapy, neoadjuvant
chemotherapy, adjuvant chemotherapy, and follow-up. All
pathological specimens were reviewed by individual insti-
tutional pathologists using the American Joint Committee
on Cancer TNM staging system relevant to time of diagnosis.
2.3. Statistical analysis
All statistical computations were performed using Stata
12/SE (StataCorp LP, TX, USA). Continuous and categorical
data were summarized as mean and rate, respectively.
Survival data were analyzed by KaplaneMeier methods and
compared by Log-rank test. All tests were considered sta-
tistically significant at p < 0.05.3. Results
3.1. Patient and disease characteristics
Data from 14,260 patients were available at the time of
final analysis. Patient and disease characteristics were
presented in Table 1. The average age of patients was 63.5
years old. Most patients were male (84.3%) and had primary
onset (84.4%). The majority patients had histology of uro-
thelial carcinoma (91.4%). Adenocarcinoma, squamous
carcinoma and other carcinomas had the rate of 1.8%, 1.9%
and 4.9%, respectively. Most patients were graded by both
1973 and 2004 WHO grading systems. A total of 8673 pa-
tients were graded by the 1973 WHO grading system. Among
them, 42.0%, 41.0%, and 17.0% of patients were grade 1, 2,
and 3, respectively. A total of 10,893 patients were graded
by 2004 WHO grading system. Among them, 16.0%, 48.7%,
and 35.3% of patients had papillary urothelial neoplasm of
Table 1 Patient and disease characteristics.
Number of patients Proportion (%)
Total 14,260 e
Age 63.5  13.2a e
Sex
Male 12,022 84.3
Female 2238 15.7
BMI 23.1  3.2a e
Onset
Primary 12,037 84.4
Recurrent 2223 15.6
Histology
Urothelial carcinoma 13,037 91.4
Squamous carcinoma 274 1.9
Adenocarcinoma 261 1.8
Others 688 4.9
Grade, 1973 WHO 8673
Grade 1 3627 42.0
Grade 2 3546 41.0
Grand 3 1466 17.0
Grade, 2004 WHO 10,893
PUNLMP 1732 16.0
Low-grade 5276 48.7
High-grade 3831 35.3
T classification
Ta 4667 32.7
Primary CIS 108 0.8
T1 5786 40.6
T2 or higher 3591 25.2
Unclear 108 0.8
Concurrent CIS 223 1.6
BMI, body mass index; PUNLMP, papillary urothelial neoplasm of
low malignant potential; CIS, carcinoma in situ.
a Mean  SD.
66 K. Li et al.low malignant potential, low grade, and high grade,
respectively. Most patients were diagnosed as non-muscle
invasive bladder cancer (NMIBC, 74.1%), including Ta
(32.7%), primary carcinoma in situ (CIS, 0.8%), and T1
(40.6%). The other 25.2% of patients had muscle invasive
bladder cancer (MIBC). Total morbidity rate of CIS was
2.4%, including concurrent CIS (1.6%) and primary CIS
(0.8%).Table 2 Treatment for NMIBCs and MIBCs.
NMIBC MIBC
n % n %
TUR 9422 89.2 547 15.2
RC 623 5.9 2304 64.1
PC 330 3.1 427 11.9
Others 186 1.8 313 8.8
Totala 10,561 3591
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle
invasive bladder cancer; TUR, transurethral resection of
bladder tumor; RC, radical cystectomy; PC, partial cystectomy.
a Patients with unclear treatments: 108 cases.3.2. Current status of diagnosis
The majority patients were diagnosed by white-light
cystoscopy with biopsy (74.3%). Application of fluores-
cence and NBI cystoscopy had additional detection rates of
1.0% and 4.0%, respectively. Only 16.9% of BCa were
detected by diagnostic TUR. The other 3.8% of patients
were recurrent cases. Ultrasonography was also a basic
diagnostic technique with the positive rate of 95.5%.
Computed tomography and magnetic resonance techniques
were used for staging with the positive rate of 96.0% and
93.8%, respectively. The applications of urinary cytology
and FISH were low (11.9% and 1.2%, respectively). However,
FISH could provide the non-invasive detection rate up to
56.9%.
3.3. Current status of treatment
Treatment methods for NMIBC and MIBC were detailed in
Table 2. Most NMIBC patients were treated with TUR
(89.2%). Other NMIBCs were treated with RC (5.9%), PC
(3.1%), and laser therapy or without operations (1.8%).
After the initial TUR, second TUR was performed in only
2.6% of NMIBC patients. At the time of second TUR, the
recurrence rate at primary site was only 15%. Post-
operative adjuvant therapy included immediate (45.7%),
induced (69.9%), and maintenance (58.7%) intravesical
instillations. A total of 9038 patients had intermediate or
high risk NMIBCs. Among them, 66.0% of patients hadFigure 1 KaplaneMeier plots of cumulative recurrence
comparing (A) immediate instillation with none; (B) mainte-
nance instillation with none.
Figure 2 Prognosis of partial cystectomy. KaplaneMeier
plots of (A) cumulative intravesicle recurrence comparing
partial cystectomy (PC) and transurethral resection (TUR) in
non-muscle invasive bladder cancers (NMIBCs); (B) tumor-free
survival comparing PC and radical cystectomy (RC) in muscle
invasive bladder cancers (MIBCs).
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16.7% of patients without any intravesical instillation after
TUR. All instillation regimens were based on chemotherapy
drugs without Bacillus Calmette-Gue´rin (BCG). The three
most common medicines were pirarubicin (51.4%), epi-
rarubicin (20.6%), and mitomycin (7.0%). Survival analysis
showed that 5-year cumulative recurrence rate was
significantly lower in patients with immediate instillation
(Fig. 1A, log-rank p < 0.001). Similarly, survival analysis
showed that 5-year cumulative recurrence rate was
significantly lower in patients with maintenance in-
stillations in intermediate or high risk patients (Fig. 1B,
log-rank p < 0.001).
Most MIBC patients were treated with RC (64.1%,
Table 2). Other MIBCs were treated with TUR (15.2%), PC
(11.9%) and reservative non-surgical therapy (8.8%).
Laparoscopic RC was performed with the rate of 35.1%,
while open RC with the rate of 63.4%. In recent years,
robotic RC began to be applied (1.5%). RC with pelvic
lymph node dissection (PLND) was performed in 73% of
patients, including 7% extended and 66% standard PLND.
The three most common urinary diversions were ortho-
topic neobladder (44%), ileal conduit (31%), and ureter-
ocutaneostomy (23%). Only 2.31% of patients were
treated with neo-adjuvant chemotherapy. Among 738
pT3eT4 patients, only 18% of patients were treated with
adjuvant chemotherapy post RC.In all, 777 patients were treated with PC (5.4%),
including 427 NMIBCs and 350 MIBCs. The predicted 5-year
cumulative recurrence rate in vesicle was comparable in
TUR and PC groups in NMIBC patients (Fig. 2A, log-rank
p Z 0.11). However, recurrence-free survival rate was
significantly lower in PC compared with RC group in MIBC
patients (Fig. 2B, log-rank p Z 0.001).4. Discussion
To our knowledge, this is the largest multicenter cross-
sectional study to evaluate the status of diagnosis and
treatment of BCa in China. Furthermore, a multicenter
database for Chinese BCa is generated and unique data for
Chinese BCa are obtained in the first time. This study
revealed the status of diagnosis and treatment of BCa had
some difference between China and Western countries.
Completely referred to clinical evidence from Western
countries was not enough to make the diagnosis and
treatment of BCa best in China. The present results could
provide evidence for clinical practice of Chinese BCa.
Screening for BCa in high risk populations is not a routine
in China. White-light cystoscopy and biopsy was still the
most common diagnosis technique for Chinese BCa. Narrow-
band imaging and fluorescence cystoscopy could provide
additional detection rates of BCa and apt to detect minimal
lesions and CIS. They can be popularized and applied widely
in China. Studies have reported that the detection rates of
BCa are 73%e96%, 4%e31%, and 8%e35% in white-light,
narrow-bind imaging, and fluorescence cystoscopy, respec-
tively [4e6], which are similar to the results in China. Recent
studies have also presented that diagnostic TUR can be
directly performed without cystoscopy in the condition of
mass found in bladder by iconography [7]. In NMIBC patients,
it can simultaneously obtain the histology and pathology and
resect the tumor. In MIBC patients, it can also provide evi-
dence for next-step treatments and prognosis. However,
diagnostic TUR is not widely applied and needs populariza-
tions in China. Ultrasonography is mostly selected for review
or patients with hematuria and is widely applied with a high
positive rate in China. However, abdominal ultrasonography
has disadvantages for BCa less than 5 mm [8]. European
Association of Urology suggests urinary cytology for patients
with high risk factors. However, a meta-analysis reports that
the sensitivity of cytology is low. In low-grade tumors, the
sensitivity is only 4%e31% [9]. In recent years, urinary mo-
lecular markers of BCa in urine have been widely used for a
new non-invasive technique for detection of BCa in the
world. The most common markers were BTAstat, BTAtrak,
NMP22, and FISH, etc. [10]. However, no ideal marker exists
which can be replaced for cystoscopy in terms of diagnosis,
treatment, follow-up, and prognosis [3]. In China, the
application of cytology and markers (mainly FISH) were low.
The detection rate of FISH in BCawas relatively high (56.9%).
With some commercial FISH kits, it can also be popularized
and applied widely in China.
Urothelial carcinoma was the most common histological
subtype (91.4%). The other subtypes were squamous car-
cinoma, glandular carcinoma, small cell carcinomas, etc. In
Western countries, the proportions of urothelial, squamous,
and glandular carcinomas are more than 90%, 3%e5% and
68 K. Li et al.less than 2%, respectively [11,12], which are similar to
proportions in China. The rate of CIS was low in China (only
2.6%), which was far less than in Western countries (24.4%)
[13]. Low rate of CIS may be the result of low incidence rate
of CIS in China or low diagnostic level. The real reason is
still uncertain, which needs further research. Application of
new diagnostic techniques such as narrow-band imaging
and fluorescence cystoscopy may have values for detection
of CIS. Nowadays, tumors were graded using both the 1973
and the 2004 WHO classifications in China. The use of the
2004 WHO classification had a trend to increase, while the
use of the 1973 WHO classification had a trend to decrease.
For unifying diagnosis of tumors and reflecting risk potential
more better, guideline of BCa in China recommends the use
of the 2004 WHO classification [3].
NMIBC were mainly treated with TUR. There may be a
significant risk of leaving residual tumor in the bladder
after the initial TUR. Residual disease is observed in up to
36% of patients [14]. Therefore, a second TUR is recom-
mended to be performed if the initial resection is incom-
plete or when a high-grade, non-muscle-invasive tumour or
a T1 tumour is detected at the initial TUR. However, the
rate of TUR was only 2.6% in China, which was far less than
the rate of 25.8%e62.4% in Western countries [15,16]. In
the meanwhile, the rate of primary recurrence was only
15% at the time of second TUR in China, which was also far
less than the rate of 36%e38.9% in Western countries
[14,17]. The reasons of differences above may be: more
complete resection of bladder tumor by the initial resec-
tion which lower the primary recurrence; surgeons were
unwilling to perform second TUR for decreasing the eco-
nomic burden and avoiding unnecessary medical dispute.
Thereafter, the inclusion criteria of second TUR should be
more restricted in China. Indication of second TUR in
Western countries should not be completely followed.
Furthermore, clinical researches of higher level are needed
for proving the applicability of second TUR in China. After
TUR, the proportion of immediate intravesical instillation
of chemotherapy was low. Survival analysis showed that 5-
year cumulative recurrence rate was lower in patients with
immediate instillation therapy than without. The result
indicated that immediate instillation of postoperative
chemotherapy should be considered immediately after TUR
in all NMIBCs without overt or suspected intra- or extrap-
eritoneal perforation or bleeding that requires bladder
irrigation. Survival analysis also showed that 5-year cumu-
lative recurrence rate was lower in intermediate and high
risk patients with maintenance instillation therapy than
without, which indicated the value of maintenance instil-
lation in these patients. In this study, all instillation regi-
mens were based on chemotherapy and no BCG was used.
By far, there exists no obvious clinical evidence apt to the
best regimen or drug [3]. Most regimens or drugs selected
for instillations still rely on the experience of surgeons.
After BCG is on the market in China, more research will be
conducted for evaluating the efficacy of BCG in Chinese
BCa.
Muscle invasive bladder cancers weremainly treatedwith
radical cystectomy. Open RC is still the standard operation
for MIBC and the most common RC in China. In recent years,
laparoscopic RC has been improved with high feasibility and
safety. In China, more than 30% of RC were performed underthe assistance of laparoscopy. Robotic assisted RC was
started to be performed with its low postoperative compli-
cations and accurate manipulation. However, Da Vinci sys-
tem is too expensive, which limits its popularization. Most
researchers suggest PLND simultaneously with RC. Without
clinical evidences of high level, the exact area of PLND is still
uncertain. Although extending the area of PLND could
dissect more lymph nodes, longer operation time and more
postoperative complications may influence the final prog-
nosis [18]. It may be an important reason of low proportion of
extended PLND in China. The three most common types of
urinary diversions in the world are orthotopic neobladder,
ileal conduit, and ureterocutaneostomy. A review reports
that the proportions of orthotopic neobladder, ileal conduit,
and ureterocutaneostomy are 38%, 42.2%, and 10.4%,
respectively [19]. In China, orthotopic neobladder was used
more frequently than in Western countries. Because ortho-
topic neobladder can maintain the quality of life and self-
image, it is adopted as a main diversion by more and more
large centers. However, the proportion of ureter-
ocutaneostomy was still high. Patients with ureter-
ocutaneostomy have high risk of stricturing on skin level and
ascending urinary tract infection. The use of ureter-
ocutaneostomy should be reduced in China, except for pa-
tients with short predicted life time, metastasis, or
intolerance to complicated operations.
Partial cystectomy is considered for NMIBC patients not
appropriate to TUR or MIBC with conservation therapy in
Western countries. A study from the USA reports the rate of
PC is only 2.8% [20]. The 5-year local recurrence rate and
tumor-free survival rate for PC were 38%e78% and w50%,
respectively [21,22]. In China, the proportion of PC was
high (5.4%). Survival analysis showed that PC could provide
prognosis no better than TUR for NMIBC patients. However,
PC could result in more complications, which make the
recovery slower. Another survival analysis showed worse
prognosis in PC compared with RC for MIBC patients.
Therefore, the use of PC should be reduced for the treat-
ment of BCa in China.
5. Conclusion
The present study concludes that the demographic char-
acteristics of BCa in China are similar to Western countries,
while some differences in diagnosis and treatment of BCa
exist. Diagnosis is mainly based on cystoscopy with biopsy.
Diagnostic TUR, fluorescence cystoscopy, NBI, and FISH
should be applied more widely in China. NMIBC is mainly
operated by TUR and too many partial cystectomies were
performed. MIBC is mainly operated by RC with PLND, but
the operations of PC and RC without PLND still exist.
Orthotopic neobladders and ileal conduits are the most two
common urinary diversions, while the proportion of ure-
terocutaneostomy is high. By investigating the current
status of diagnosis and treatment of Chinese BCa, this study
could provide evidences for revisions of the guideline of
BCa in China.
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